07:00 , Sep 19, 2016 |  BC Week In Review  |  Clinical News

Omega-3 phospholipids: Bridging study data

An open-label, 4-way crossover bridging study in 56 healthy volunteers showed that a single dose of 4 g oral CaPre met the primary endpoint based on EPA and DHA levels. Specifically, levels of EPA and...
07:00 , May 11, 2015 |  BioCentury  |  Finance

White space with graybeards

Flagship Ventures has decided the best way to identify and explore white space is by tapping large partners that can lend insights early in the company creation process on topics ranging from discovery to reimbursement....
03:39 , Dec 6, 2014 |  BC Extra  |  Company News

GSK staying put with established products

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) dropped its plan to divest a portfolio of U.S. and European established products after evaluating bids from potential buyers. GSK spokesperson Melinda Stubbee declined to provide further details. In July, the...
08:00 , Nov 6, 2014 |  BC Innovations  |  Targets & Mechanisms

Greasing insulin

An entirely new class of fatty acids has just been discovered that potentially is more potent than the w-3 fatty acids found in fish oil. The new fatty acids-which work through G protein-coupled receptor 120,...
08:00 , Feb 3, 2014 |  BioCentury  |  Regulation

Lipid advice in Europe

A lack of clarity about requirements for cardiovascular safety and outcomes data in updated EMA guidance means companies developing lipid-modulating therapies will need to seek individual advice from the European regulator as early as possible...
07:00 , Sep 16, 2013 |  BC Week In Review  |  Company News

Teva, BASF, Par Pharmaceutical endocrine/metabolic news

The U.S. Court of Appeals for the Federal Circuit reversed in part a lower court's 2012 ruling upholding U.S. Patent Nos. 5,656,667 and 5,502,077 covering Pronova Biopharma ASA 's lipid-lowering drug, Lovaza . Chemicals company...
07:00 , May 13, 2013 |  BC Week In Review  |  Clinical News

N-3 polyunsaturated fatty acids: Phase III data

Researchers at the institute reported data from a double-blind, Italian Phase III trial in 12,513 patients with multiple cardiovascular risk factors or atherosclerotic vascular disease who had not had a myocardial infarction (MI) showing that...
08:00 , Jan 21, 2013 |  BC Week In Review  |  Company News

Pronova, Takeda sales and marketing update

Takeda launched Lotriga in Japan to treat hyperlipidemia. Takeda has exclusive, Japanese development and marketing rights to the omega-3-acid ethyl esters from Pronova under a 2005 deal. Takeda said the National Health Insurance price for...
08:00 , Dec 17, 2012 |  BioCentury  |  Finance

Herkulean return

Herkulean return Herkules Capital, the largest shareholder of Pronova Biopharma ASA (OSE:PRON), is looking at a more than 13x return when chemicals company BASF AG (Xetra:BAS; LSE:BFA) acquires the biotech this week. Herkules first invested...
08:00 , Dec 3, 2012 |  BC Week In Review  |  Company News

Pronova, BASF deal

Chemicals company BASF will acquire Pronova for NOK12.50 per share in cash, or about NOK3.8 billion ($662.5 million). The price is a 4% premium to Pronova's close of NOK12 on Nov. 20, before the deal...